Skip to main content
. 2019 Aug 7;317(4):C857–C866. doi: 10.1152/ajpcell.00281.2019

Fig. 2.

Fig. 2.

Discovery of pranlukast in a high-throughput screen of the US Food and Drug Administration library. A: representative traces of an Ozzy-quenching assay with pranlukast. Hypotonic solutions [hypotonic (hypo) bath; hypotonic bath + 100 μM pranlukast] were added at time “a” and NaI was added at time “b”. Inset: structure of pranlukast. B: dose-dependent inhibition of volume-regulated anion channel using Ozzy-quenching assay (n = 5).